Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.

ABSTRACT:

Objectives

Anaplastic thyroid cancer (ATC) is the most aggressive and fatal thyroid malignancy. Currently, there still exists a paucity of literature studying the relationship between available ATC-targeted therapy, immunotherapy, and survival. We aim to investigate how systemic therapies affect survival outcomes in ATC.

Methods

A single-tertiary-institution chart review of patients diagnosed with advanced-stage ATC, and who underwent surgery as part of their treatment, was performed between 2000 and 2023, with 41 patients included. Demographics, clinical characteristics, and survival data were collected and analyzed via Kaplan-Meier and Cox proportional hazards analyses.

Results

54% of patients were female, and average age was 67.4 years old. The most common mutation

SUBMITTER: Evans LK 

PROVIDER: S-EPMC11635144 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature